The FTC Finds United Health’s OptumRX Is Engaged In Widespread Price Gouging
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from price gouging.

Pharmacy benefit managers inflated drug prices by $7.3B

 · 2dDealbreaker on MSN
Pharmacy Benefit Managers Not Thrilled With FTC Report Finding Pharmacy Benefit Managers Raise Drug Prices
 · 3dCampus Safety Magazine
FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging
 · 4dHealthcare Dive
FTC releases second report slamming pharmacy benefit managers
Modern Healthcare5d
Big 3 PBMs reaped $7.3B from generic specialty drug markups: FTC
The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, OptumRx and Express Scripts.
Top three insurers reaped $7.3 billion through their drug middlemen's markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" prescription price hikes of 1,000% or more.
UnitedHealth Charged Cancer Patients 5000%, Bombshell FTC Report Claims
The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands of percent.
How UnitedHealth and Rivals Made $7.3 Billion Marking Up Drugs: FTC
The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension drug.
PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through
FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
PBMs Under Fire Again, But Despite Bipartisan Pressure Reforms May Be Elusive
As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months critical of pharmacy benefit managers.
centerforbiosimilars5h
FTC Releases Second Report on PBMs Meddling in Generic Drug Markets
The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the Federal Trade Commission (FTC)’s second interim report on PBM practices.
Scioto Post1h
Amid federal uncertainty, advocates and officials highlight state-level antitrust fights
By: Marty Schladen It’s unclear whether Donald Trump will continue the Biden administration’s focus on antitrust enforcement when he again becomes president on Monday. But advocates and state officials say that regardless of what Trump does,